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Abstract In this study, an integrated approach is developed
for the formation, identification and biological characteriza-
tion of electrochemical conversion products of p38α
mitogen-activated protein kinase inhibitors. This work dem-
onstrates the hyphenation of an electrochemical reaction cell
with a continuous-flow bioaffinity assay and parallel LC-
HR-MS. Competition of the formed products with a tracer
(SKF-86002) that shows fluorescence enhancement in the
orthosteric binding site of the p38α kinase is the readout for
bioaffinity. Parallel HR-MS
n experiments provided informa-
tion on the identity of binders and non-binders. Finally, the
data produced with this on-line system were compared to
electrochemical conversion products generated off-line. The
electrochemical conversion of 1-{6-chloro-5-[(2R,5S)-4-(4-
fluorobenzyl)-2,5-dimethylpiperazine-1-carbonyl]-3aH-
indol-3-yl}-2-morpholinoethane-1,2-dione resulted in eight
products,three ofwhichshowedbioaffinity inthecontinuous-
flowp38α bioaffinityassay used. Electrochemical conversion
of BIRB796 resulted, amongst others, in the formation of
the reactive quinoneimine structure and its corresponding
hydroquinone. Both products were detected in the p38α
bioaffinity assay, which indicates binding to the p38α
kinase.
Keywords Electrochemicaloxidation.p38mitogen-
activatedproteinkinase.Highresolutionmassspectrometry.
Hyphenation.Bioassays
Introduction
Electrochemistry (EC) is increasingly described as a tool to
support the formation and identification of drug oxidation
products [1]. Efforts are reported to mimic a human metab-
olite profile [2] or to produce specific reactive metabolite
species [3]. The application of electrochemical techniques
specifically focused at drug development is reviewed by
Hillard et al. [4]. These applications are mainly directed at
the study of reactive oxygen species, oxidation and reduc-
tion of prodrugs, and the alkylation of DNA. Bauman and
Karst [5] recently described the principles and use of on-line
electrochemistry–mass spectrometry (EC-MS) in drug me-
tabolism studies. Jurva et al. systematically compared the
oxidation of drugs by EC-MS and by cytochrome P450s [6].
This approach provides chemical information on the prod-
ucts formed by electrochemistry and facilitates the compar-
ison with in vitro incubation models [7, 8]. The chemical
information obtained can eventually be used to correlate
biological action of already characterized metabolites to
the products analysed. However, this is not feasible for
newly formed products for which no biological data are yet
available. Still, few examples in EC-related drug metabolism
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the best of our knowledge, none tested for a specific target
enzyme or receptor. More importantly, in studies employing
EC-MS or EC-LC-MS, biological testing seems to be a com-
pletely new development. This is surprising because the bio-
logical activity of the metabolites towards the drug target is of
utmost importance for the efficacy of a drug. For many years,
we have been developing hyphenated screening assays to
obtain chemical and biological information in a combined
manner [11]. This resulted in several approaches to assess
bioaffinity,e.g.,on-linereceptorbinding[12],enzymeactivity
assessment [13], bacterial growth inhibition [14], as well as
several other strategies which allowed us to identify and
characterize bioactive compounds [15–17] in (complex) mix-
tures. These mixtures included natural extracts, crude synthe-
sis products, medicinal chemistry compound libraries,
degradation products by light or harsh chemical conditions,
as well as in vitro metabolic incubations.
The implementation of a device for electrochemical
oxidation in our on-line screening platform would lead
to a fully automated process of formation of drug-related
chemical entities followed by their simultaneous chemical
and biologicalcharacterization. Thisleads toa quick feedback
between the modifications of a lead compound and their
consequences for binding to the drug target. Furthermore,
instable and/or reactive products could be analysed directly
after their formation and as such have less chance of
degradation.
In this paper, we describe the hyphenation of EC with our
recently developed liquid chromatography (LC)–on-line
p38α mitogen-activated protein kinase binding assay
(p38α bioaffinity assay) with parallel high resolution MS
[18]. EC provides relatively clean samples and has shown to
facilitate the formation of interesting molecules for drug
research [19]. The p38α mitogen-activated protein kinase
(p38α kinase) is a prominent example of a drug target
kinase [20] and is heavily involved in inflammation
processes [21]. The hyphenation of these techniques to
develop a fully integrated platform can facilitate the hit-
to-lead selection process in drug discovery. This com-
plete hyphenation of EC with LC and ultimately with
parallel detection by p38α bioaffinity assay and high resolu-
tion MS combines modification with separation, bioaffinity
determination and structure elucidation on a new level of
integration.
Materials and methods
Chemicals
Acetonitrile, methanol (LC-MS grade), and formic acid (ULC-
MS grade) were obtained from Biosolve (Valkenswaard, the
Netherlands). Water was produced by a Milli-Q device of
Millipore (Amsterdam, the Netherlands). Nitrogen 5.0 was
purchased from Praxair (Vlaardingen, the Netherlands) and
used in all MS experiments. SKF-86002 (SKF) was delivered
by Merck KGaA (Darmstadt, Germany). Enzyme-linked im-
munosorbent assay blocking reagent was purchased from
Roche Diagnostics (Mannheim, Germany). Ammonium ace-
tate and ammonium hydrogen carbonate were obtained from
Mallinckrodt Baker (Deventer, the Netherlands). Fused silica
tubing (250-μm inner and 375-μm outer diameter) covalently
coated with polyethylene glycol was obtained from Sigma-
Aldrich (Schnelldorf, Germany). Human recombinant p38a
kinase, BIRB796, TAK715, 1-(6-chloro-5-((2R,5S)-4-(4-fluo-
robenzyl)-2,5-dimethylpiperazine-1-carbonyl)-3aH-indol-3-
yl)-2-morpholinoethane-1,2-dione (DMPIP), and SB203580
were a kind gift of MSD Research Laboratories (Oss, the
Netherlands). Structures of the kinase inhibitor standards used
can be found in Fig. 1. All other chemicals were from Sigma-
Aldrich (Schnelldorf, Germany).
Instrumentation
A schematic representation of the complete on-line setup is
shown in Fig. 2. The system consists of four modules: (a) an
electrochemical reaction cell, (b) an LC system, (c) a
continuous-flow bioaffinity assay unit, equipped with a
fluorescence detector, and (d) a mass spectrometer.
Fig. 1 Structures of the kinase inhibitors used for electrochemical
conversion experiments
368 D. Falck et al.A Roxy electrochemical reaction cell (Antec Leyden,
Zoeterwoude, the Netherlands) equipped with a glassy car-
bon electrode was controlled by the Decade II Potentiostat
either manually or under Dialogue software control (Antec
Leyden). The 10 μM kinase inhibitor standards, dissolved in
25% ACN and 75% 1 mM aqueous buffer, were infused at a
flow rate of 5 μL/min with a Harvard Apparatus (Hollister,
USA) syringe pump. The conversion products were collected
either in an autosampler vial (“off-line” mode) or in 100 μL
volume PEEKtubing(“on-line” mode) serving asaninjection
loop mounted in a remote controlled six port valve (VICI,
Schenkon, Switzerland).
In the off-line mode, collected fractions were injected via
the autosampler, whereas in the on-line mode the six port
valve with the 100 μL PEEK tubing acted as the injection
valve to a Shimadzu LC system (‘s Hertogenbosch, the
Netherlands), consisting of two LC-10ADvp pumps, a
DGU-14A solvent degasser, a SIL-10ADvp auto injector,
two CTO-10ASvp column oven, an SPD-10Avp UV-
detector and a SCL-10Avp system controller. The LC sepa-
ration was performed on a Waters Xbridge C18 column
(2.1×100 mm I.D., 3.5 μm particles). The mobile phases
consisted of 99% water with 1% methanol (solvent A) and
1% water with 99% methanol (solvent B), both containing
0.01% formic acid. A generic gradient was applied for the
separation: isocratic for 2 min at 20% B, gradient to 90% B
until 18 min, isocratic at 90% B until 22 min, a gradient
back to 20% B until 23 min, and isocratic re-equilibration at
20% B until the end of the run at 30 min. The flow rate was
113 μL/min. The column temperature was kept at 40 °C. All
standards eluted with significant retention, which provided
sufficient resolution for the separation of products with
slightly differing polarities.
Initial off-line experiments were performed with the EC
unit and an LC-MS system, without the p38 bioaffinity assay
attached, in order to optimize the EC conditions. For this, the
LC system was coupled via an electrospray ionization (ESI)
interface to a Thermo Finnigan LCQ Deca ion trap mass
spectrometer (LRMS; Breda, the Netherlands). Experimental
conditions for the ion trap MS were as follows: Capillary
temperature 200 °C, sheath gas flow 45 arbitrary units, aux
gas flow 5 arbitrary units, source voltage 5 kVand capillary
voltage 6 V. The instrument was used in positive-ion ESI
mode for full spectra acquisition between m/z 150 and 650.
In on-line experiments with the complete setup, a post-
column split was applied (see Fig. 2), with 13 μL/min of the
LC mobile phase being directed to the p38α bioaffinity
assay and 100 μL/min to the MS system. The post-column
fluorescence enhancement based bioaffinity assay towards
the p38α kinase was identical to the system previously
described by us [18]. Important features of the system are
shown in Fig. 2. Competition of the formed products with a
tracer (SKF) that shows fluorescence enhancement in the
orthosteric binding site of the p38α kinase is the readout for
bioaffinity. Stability of the flow system is essential for the
quality of the assay as small changes in the reaction param-
eters have relatively pronounced consequences in the signal.
Therefore, a stable reagent flow is important in order to keep
thenoisetoaminimum.Thiswasachievedbyalinearsetupof
an LC pump, a pulse dampener, a restriction capillary, and a
superloop. The state-of-the-art LC pump delivered a constant
flow of water. The pulse dampener was based on an imper-
meable membrane and had a comparably extensive water
reservoir. The restriction capillary was chosen to produce ca
70 bar backpressure at the applied flow rate of 50 μL/min. As
a result, a constant and stable flow entered the superloop. The
superloop served as a reagent reservoir of constant volume
which released exactly the same flow rate as it received.
Compared to a delivery by the pump alone, reagents were
also more easily cooled and pump maintenance was reduced
which further improved the stability of the system.
Parallel to the p38α bioaffinity assay, the electrochemical
conversion products were analysed using a Shimadzu ion-
trap time-of-flight hybrid mass spectrometer (LC-IT-TOF-
MS), equipped with an ESI source and operated in positive-
ion mode to obtain accurate m/z values for [M + H]
+ and
fragment ions. The ESI needle voltage was set to 4.5 kV,
while the source heating block and curved desolvation line
temperature were set to 200 °C. Drying gas pressure was set
at 62 kPa and nebulizing gas was applied at a flow-rate of
1.5 L/min. MS
2 and MS
3 spectra were acquired in data-
dependent mode with the following settings: full-spectrum
MS with m/z 200–650, MS
2 with m/z 150–650, and MS
3
acquisition with m/z 100–650 with ion accumulation time of
10 ms, precursor isolation width of 3 Da, and collision
energy set at 75% for TAK715 and 50% for all other com-
pounds. The accurate-mass fragmentation data obtained
were used for structure identification. External calibration
of the instrument was based on sodium TFA clusters and
allowed a mass accuracy lower than 5 ppm. From the
Fig. 2 Scheme of the on-line setup. (1) On-line electrochemical con-
version of inhibitor. (2) Gradient LC separation of products formed. (3)
Split of 1:9 to MS and p38α bioaffinity assay. (4) Reaction coil for
enzyme binding. (5) Addition of tracer molecule. (6) Detection of
enzyme tracer complex by fluorescence and parallel HR-MS
n for
structural information of binders
On-line electrochemistry–bioaffinity screening 369measured accurate mass, the elemental composition of the
products and their fragment ions were calculated. In order to
extract the relevant elemental compositions, restrictions were
applied to exclude those which have more atoms of any kind
than the substrate plus possible modifications. This is reason-
able because the products are linked to the substrate by elec-
trochemical modification. For fragments, the elemental
composition of the precursor ion was used as restriction. The
fewcompositionsleftwereanalysedforelectrochemicalmod-
ifications possibly leading to the formation of products with a
specific composition. Where CID fragments were concerned,
this analysis was based on reasonable neutral losses. The
procedure was sufficient to restrict the discussion to only
one elemental composition.
Optimization of electrochemical conversion
For flow-through electrochemical reaction cells, important
parameters reported are pH, electrode voltage, organic modi-
fier content, and flow rate [5, 6]. Several techniques can be
used to find the optimal conditions. Those include cyclic
voltammetry, direct EC-MS coupling, and off-line EC and
LC-MS experiments [5, 22]. The latter method was applied
in this study. We evaluated per substrate four different poten-
tials (0, 0.4, 0.8, 1.2, and 1.5 V) and four different pH values
(3.5,5.0,7.0,and10.0).Thefourdifferentbuffersusedtovary
the pH were: an ammonium formate/formic acid buffer with
pH 3.5, an ammonium acetate/acetic acid buffer with pH 5.0,
and two ammonium hydrogen carbonate buffers with pH 7.0
and 10.0, adjusted with formic acid and sodium hydroxide,
respectively. Each series resulted in 20 samples. The series
wasinjectedinduplicate,whichduetothe30minLCruntime
resulted in a well-defined 10 h difference between the two
duplicate analyses of the same sample. This provided an
indication of the stability of the products formed.
From the off-line optimization data, optimum conditions
were selected to be applied in the on-line mode, using the
complete setup. These conditions are summarized for the
three model compounds in Table 1.
Results and discussion
In this study, an integrated approach is developed for the
formation, identification, and biological characterization of
conversion products derived from p38α kinase inhibitors.
This work demonstrates the hyphenation of an electrochem-
ical reaction cell with a continuous-flow bioaffinity assay
and parallel LC-HR-MS. The recently developed p38α bio-
affinity assay, based on fluorescence enhancement, was used
as a model assay to investigate the possibilities of this
combination, but the approach is not limited to this specific
continuous-flow assay. Parallel HR-MS
n experiments pro-
vide information on the identity of binders and non-binders.
Finally, the data produced with this on-line system were
compared to that of off-line generated electrochemical con-
version products.
First of all, the electrochemical conversion of the kinase
inhibitors had to be optimized for substrate conversion and
product formation. Formation and identification of bioaffin-
ity products is the ultimate goal of the method. High sub-
strate conversion simplifies the bioaffinity assessment by
reducing the interference of the unmodified inhibitor. The
off-line and on-line approaches employ the same flow-
through EC instrument which is operated under the same
experimental conditions in both cases. Therefore, the off-
line data generated for validation of the on-line setup can be
used to extract the optimal electrochemical reaction condi-
tions for both setups. An excerpt of the off-line generated
data can be found in the Electronic Supplementary Material
Figure S2. Although the EC and LC-MS approach can be
considered laborious for reaction optimization only, it has
advantages over other methods. Cyclic voltammetry will not
give any information on product formation and direct EC-
MS analysis can be strongly hampered by ion suppression
effects as well as by unwanted up front fragmentation.
Figure 3 shows an overlay of the bioaffinity traces of on-
line electrochemistry-LC-p38α bioaffinity assay experi-
ments and the relevant extracted ion chromatograms (EIC)
from the simultaneous LC-MS experiments for the com-
pound DMPIP (C28H30ClFN4O4,[ M+H ]
+ with m/z
541.2012). Clearly, bioactive products were formed under
all conditions applied, although in different relative concen-
trations. The four negative peaks in the affinity chromato-
gram indicate binding/affinity of three conversion products
to the p38α kinase by displacing the tracer ligand upon
elution from the LC column. The affinity is linked in the
same figure to the EIC for identification of the binders. As
the products showing affinity are the same under all con-
ditions, the EICs are derived from one measurement. As
reported previously, the retention times in the bioaffinity
detection as well as in the MS detection are very stable
(<3% relative standard deviation) [18]. This is expectable
with state-of-the-art LC equipment, even more so with
Table 1 Optimized electrochemical conversion conditions for DMPIP,
BIRB796, and SB203580
Inhibitor EC conditions
pH Potential
DMPIP 3.5 +1.2 V −1.5 V
10.0 +1.2 V
BIRB796 3.5 +0.8 V
10.0 +0.8 V
SB203580 5.0 +1.5 V
10.0 +1.5 V
370 D. Falck et al.reagent delivery through pump, pulse dampener, restriction
capillary and superloop which ensures stability of the bio-
affinity trace. An increase in peak tailing is the only differ-
ence expected between bioaffinity and MS chromatograms
in terms of chromatographic parameters. Even this only
applies to highly nonpolar compounds as a result of the low
organic modifier content of the bioaffinity assay. Therefore,
the bioaffinity and MS chromatograms are matched by their
stable retention time difference. The validity of this retention
time difference can be double checked if a known binder is
present inthe mixture,inthiscasethe substrate ofthe EC.The
correlation of a bioaffinity peak with an EIC peak is achieved
with high certainty because a margin of twice the maximum
relativestandarddeviation ofthe retentiontime, inthiscaseca
30s,isapplied.IfmorethantwoEICpeakswouldbematched
within ±30 s to a bioaffinity peak, both compounds were
possibly responsible for the bioaffinity signal. Fortunately,
this case did not occur in the investigation. Please note that
bioaffinity chromatograms were correlated with EIC at the
front of the peak. In this way, peaks are more easily assessed
when overloading of either readout leads to broad peaks with
poorly defined maxima.
The major affinity peak is due to the unmodified kinase
inhibitor, DMPIP. The seemingly large broadening of this
affinity peak is due to the sigmoidal dose–response charac-
ter of the bioassay. Based on the bioaffinity profile, the
product with m/z 539.1902 (Δ −2.011 u) showed to be the
main bioactive product in the oxidative mode. However, in
the reductive mode, this product was less abundant and a
product with m/z 472.1461 (Δ −69.0551 u) also showed
significant binding to the p38α kinase. In both the reductive
and the oxidative mode, a minor affinity peak was observed
corresponding to hydroxylated DMPIP, with m/z 557.1962
(Δ +15.9950 u).
Identification of the (bioactive) products was done using
the HR-MS
n data obtained in parallel with the bioaffinity
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Fig. 3 Correlation of bioaffinity profiles (top) and HR-MS traces (bottom) of electrochemical conversion products related to DMPIP
On-line electrochemistry–bioaffinity screening 371measurements. Based on the fragmentation of the unmodi-
fied kinase inhibitor, the sites of modification were identi-
fied as far as possible. The fragmentation of DMPIP allowed
the annotation of characteristic fragments to be used for the
determination of the modification sites. Figure 4 shows the
structure of DMPIP with the characteristic parts of the
molecule involved in the fragmentation reactions.
Important fragments observed in the MS/MS spectra of
DMPIP are C + D with m/z 319.0480 and C with m/z
206.0003. Table 2 summarizes the identification study.
Below, the MS structure elucidation of two ions is dis-
cussed in detail. A full description of the structure elucida-
tion for all ions observed is avoided in order to focus the
discussion on the innovative combination of techniques. As
an example, the MS and MS/MS spectra for the bioactive
product with m/z 472.1461 are given in Fig. 5. The m/z
difference compared to the parent compound is Δ
−69.0551 u, consistent with a net loss of C4H7N. The data
indicate that the molecule is modified in the D part, see
Fig. 4. Parts A + B and C are detected unmodified, whilst
the fragment of C + D shows the net loss of C4H7N.
Fragmentation of the [M + H]
+ additionally results in de
neutral loss of CO2, leading to an unmodified B + C frag-
ment. The characteristic losses of C4H7N and CO2 prove the
hydrolysis of the amide in part D to a carboxylic acid, which
is further supported by the MS
3 fragments (data not shown).
Therefore, full structure elucidation could be achieved by
MS
n analysis for this product. For the product with m/z
539.1902, attributed to a dehydrogenation of part B, abso-
lute identification is not possible. The attribution is made by
exclusion. As fragment CD is observed unchanged, modifi-
cation in parts C and D is excluded. Since the dehydroge-
nation is observed in a BC fragment and C has already been
excluded, the modification has to be in part B. A modifica-
tion ‘across’ parts B and C can also be excluded, as the
connecting amide has no hydrogen atoms to lose and as any
other possibility would have to involve the formation of a
new bond. This would require proximity which is hindered
by the rigid structure of the C part and the connecting amide.
The only likely crosslink between B and C would produce
the loss of HCl instead of H2. All other B–C crosslinks
would lead to new carbon-carbon bonds which would block
the formation of the CD fragment.
Other products were identified in a similar way. The prod-
ucts of oxidation in part D (m/z 472.1461 and m/z 557.1962)
as well as dehydrogenation in part B (m/z 539.1902) of
DMPIP all retained the affinity for the p38α kinase, see
Table 2. Products not showing bioaffinity include methoxyla-
tion of part A (m/z 571.2110, C29H33ClFN4O5
+; see also
below), cleavage of methane from part B (m/z 525.1720,
C27H27ClFN4O4
+) and the loss of C3H4 from part B (m/z
501.1715, C25H27ClFN4O4
+). The electrochemically induced
cleavage of part A resulted in a product with m/z 431.1476
(C21H24ClN4O4
+).
The bioaffinity assessment of the products based on the
inhibitor BIRB796 (C31H37N5O3,[ M+H ]
+ with m/z
528.2975) showed that next to BIRB796 itself, two bioactive
electrochemical conversion products were formed. Figure 6
shows the extracted ion chromatograms of the three bioactive
compounds aligned with the bioaffinity trace. The two
additional bioactive compounds were the main conversion
products, being identified as the quinoneimine (m/z
413.1985, C25H25N4O2
+, Δ 115.0990 u) and the hydroqui-
none (m/z 415.2134, C25H27N4O2
+, Δ 113.0841 u), both
being present in all conversion samples.
Interestingly, Regan et al. described the structure-activity
relationships of BIRB796 and some of its fragments [23].
The hydroquinone was found to bind to the kinase, while the
reactive quinoneimine was addressed neither in this publi-
cation nor elsewhere in literature. The fact that we can detect
bioaffinity of the reactive quinoneimine underlines the im-
portance of a quick and clean sample handling technology
between formation and analysis of the conversion products.
In this respect, our on-line approach can be of added value
with respect to the assessment of the affinity of reactive spe-
cies. Other electrochemical conversion products of BIRB796
were not bioactive. These included a product with m/z
230.1652 corresponding to C14H20N3
+ and a low abundant
product with m/z 273.1710 corresponding to C15H21N4O,
+
co-eluting with the unmodified BIRB796. Structure proposals
can be found in the Electronic Supplementary Material
Figure S1. Oxidation at pH 7.0 and 10.0 resulted in two
additional products with m/z 386.1863 (C24H24N3O2
+)a n d
411.1821 (C25H23N4O2
+).
For SB203580 and its conversion products, affinity deter-
mination was hampered by the auto-fluorescence of SB203580
and its products at the wavelengths used for the detection of the
enzyme-tracer complex in the p38α bioaffinity assay. Electro-
chemicalconversionofSB203580(C21H17FN3OS
+,[M+H]
+
with m/z 378.1071) resulted in the formation of single (m/z
394.1026) and double oxygenated analogues (m/z 410.0969).
The main product could be identified as the sulfone product
based on its fragmentation pattern described previously by
Henklova et al. [24]. The rather scarce fragmentation of
SB203580 did not allow proposing structures of the other
products generated by electrochemical conversion.
AB C D
Fig. 4 Structure of DMPIP and characteristic parts for MS/MS iden-
tification of electrochemical conversion products
372 D. Falck et al.In order to compare the on-line formation with the con-
ventional off-line generated products, a set of off-line elec-
trochemical conversion experiments was conducted. This
included variation of pH and electrochemical potential for
the conversion of the inhibitors. The samples were measured
twice, once immediately after generation and once with an
additional storage time of 10 h. In this way, a focus was set
on the effects of storage as a major difference between the
off-line and on-line approach. For DMPIP and SB203580,
no differences were observed in the conversion profiles
between off-line and on-line conversion and analysis. This
means that product formation is comparable between the
two modes. The results of the off-line experiments also help
to explain the origin of the methoxylation product for
DMPIP. It may be suggested that the methoxylation does
not take place in the EC cell, but rather via a reaction of a
Table 2 Identification of electrochemical conversion products related to DMPIP based on high resolution MS
n experiments (for explanation: see
text)
Tr in min.  [M+H]+ Change 
in 
formula 
Molecular 
formula
MSn
AB C  CD  other 
fragments 
16.1 541.2012  -  C28H31 ClFN4O4
+ - 
9.3 431.1481 -C7H6F  C21H25ClN4O4
+ -  -  D 
11.9 501.1699 -C3H4 C25H27ClFN4O4
+ - -  BC-C3H4
12.8 525.1699  -CH4 C27H27ClFN4O4
+ -CH4 -  - 
14.0 472.1461  -C4H7N  C24H24ClFN3O4
+ -C4H7N  -CO2
15.6 557.1962  +O  C28H31ClFN4O5
+ +O  - 
15.6 529.1649 -C2H4 +O  C26H27ClFN4O5
+ -  A, 
-CO, -H2O 
17.5 571.2118  +CH2O C29H33ClFN4O5
+ - -  D, -H2CO 
19.6 539.1902  -2H  C28H29ClFN4O4
+ -  -  BC-2H 
MS fragmentation is not to be confused with EC modifications (e.g., hydrolysis). For conclusions on nature and site of the EC modifications drawn
from the MS
n data, please refer to the text. Binding to p38α kinase is defined as an S/N ratio of >3 in the p38α bioaffinity assay (see also Fig. 3).
The products showing bioaffinity are underlined in gray
Fig. 5 MS and MS/MS spectra
of the electrochemical
conversion product of DMPIP,
with m/z 472.1461. Annotations
related to the parent structure
(Fig. 4) are included in the
spectra
On-line electrochemistry–bioaffinity screening 373reactive intermediate with methanol in the LC mobile phase.
However, the off-line experiments provide evidence against
this. The off-line data, shown in Electronic Supplementary
Material Figure S3, are not consistent with an intermediate
reaction with the LC eluent because, if it would be reacting,
the amount of methoxylated product should be the same or
less after storage (depending on the stability of the interme-
diate). However, the data actually show a higher abundance
of methoxylated product after storage which indicates a
reaction of an intermediate within the EC reaction mixture.
Furthermore, if a reaction would take place during the
chromatographic step, the peak shape of the methoxylated
product would be seriously deteriorated. This is not ob-
served. For BIRB796, differences were observed between
off-line and on-line conversion products. The peak area of
the reactive quinoneimine significantly decreased in
the duplicate measurement after 10 h (see Electronic
Supplementary Material Figure S2), whilst in the pH 7
samples the hydroquinone was only present after 10 h.
The products with m/z 230 and m/z 273 had an increased
peak area in all duplicate samples and can therefore be either
considered as secondary conversion products or degradation
products. This is a direct consequence of the storage and
handling steps and can be avoided in the on-line approach
presented in this paper.
Conclusion
Electrochemical conversion of drug molecules has already
been demonstrated to be a valuable tool to assist in drug
metabolite identification studies. As an additional valuable
feature,weshowedthatelectrochemistrycoupled on-linewith
LC-MS/bioassay can be used for the generation of small
focused libraries of bioactive structures closely resembling
the parent structures and assessment of their bioaffinity pro-
file. The hit rate in these focused libraries can be significant.
With the integration of direct affinity assessment of the elec-
trochemical conversion products, one can quickly determine
critical positions of a molecule influencing its affinity towards
the target protein. Moreover, the on-line hyphenation of
formation with identification and affinity determination
strategies allows the affinity assessment of reactive species
since sample handling steps and times are significantly re-
duced. The latter was clearly demonstrated by the affinity
determination of the reactive quinoneimine of the BIRB796
inhibitor. All of these results stress the importance of
employing biological characterization as an integral part
of EC studies concerned with drug metabolism or lead dis-
covery/optimization.
In principle, the on-line integrated setup could be ex-
panded to an automated system applicable in routine analy-
sis. Instead of by infusion, the parent compounds could be
flow-injected into the electrochemical reaction cell. Solvent
select valves could be used for convenient and automated
changing of the solvent composition and pH. Evidently, the
subsequent electrochemical conversion can also be fully
automated and controlled via the appropriate controlling
software during the analytical runs. The complete setup
should be capable of implementation in fully automated
and integrated analytical workflows in drug discovery
laboratories.
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